Scarica l'app Stockscreener
1.59
1.27%
0.02
Precedente Chiudi:
$1.57
Aprire:
$1.57
Volume 24 ore:
65,086
Relative Volume:
0.90
Capitalizzazione di mercato:
$83.44M
Reddito:
-
Utile/perdita netta:
$-4.61M
Rapporto P/E:
-12.68
EPS:
-0.1254
Flusso di cassa netto:
$-3.10M
1 W Prestazione:
+2.58%
1M Prestazione:
+0.00%
6M Prestazione:
-14.97%
1 anno Prestazione:
-29.33%
Intervallo 1D:
$1.5635
$1.60
Intervallo di 1 settimana:
$1.42
$1.60
Portata 52W:
$1.42
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Nome
Okyo Pharma Limited
Settore
Industria
Telefono
-
Indirizzo
-
Compare OKYO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.59 | 83.44M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Piper Sandler | Overweight |
| 2025-12-08 | Iniziato | B. Riley Securities | Buy |
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO Pharma And The Small-Cap Eye Care Story - Kalkine Media
OKYO Pharma Ltd (OKYO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3 - Stock Titan
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma (OKYO) director awarded options on 3,500 common shares - Stock Titan
OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85 - Stock Titan
Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares - Stock Titan
OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85 - Stock Titan
OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners - Stock Titan
OKYO Pharma Slips 1.85% as Shares Test Key Support LevelTrend Following Picks - newsline.com
OKYO Pharma (OKYO) Retreats Toward Support as Biotech Sector Faces HeadwindsInverse ETF Flow - newsline.com
OKYO Pharma (OKYO) director reports detailed stock option grants - Stock Titan
OKYO H2'25 Earnings: EPS estimate is (0.08) USD - TradingView
OKYO Pharma (OKYO) director discloses stock and option holdings - Stock Titan
[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership - Stock Titan
OKYO Pharma Edges Lower, Holds Steady Near Key Support LevelStop Loss Guidance - newsline.com
OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma (OKYO) Edges Higher on Modest Gains, Holds Above Key SupportSentiment Divergence - The Legal Advocate
OKYO H2'25 Earnings: revenue estimate is 0 USD - TradingView
OKYO Pharma Shares Edge Higher as Biotech Momentum BuildsMFI Overbought - The Legal Advocate
OKYO Pharma expands scientific advisory board with cornea expertICYMI - Proactive financial news
OKYO Pharma Ltd (OKYO) CFO details equity and option positions - Stock Titan
OKYO Pharma (OKYO) CEO discloses multiple stock option positions - Stock Titan
What Makes OKYO Pharma (OKYO) a New Buy Stock - Yahoo Finance
Should I buy OKYO Pharma (OKYO) - Zacks Investment Research
Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board - VisionMonday.com
OKYO Pharma adds Marta Sacchetti to scientific advisory board By Investing.com - Investing.com India
OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com - Investing.com South Africa
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment - Proactive financial news
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board - Yahoo! Finance Canada
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain - TipRanks
OKYO Pharma adds Marta Sacchetti to scientific advisory board - Investing.com
OKYO Pharma appoints Marta Sacchetti to advisory board - Investing.com
OKYO Pharma (OKYO) deepens NCP program with new advisory board expert - Stock Titan
OKYO Pharma Limited Expands Scientific Advisory Board with Appointment of Marta Sacchetti - marketscreener.com
Point72 and Steven A. Cohen report 0% stake in OKYO (NASDAQ: OKYO) - Stock Titan
Woodline Partners reports 7.0% stake in OKYO Pharma (NASDAQ: OKYO) - Stock Titan
Sirenia Capital (OKYO) files Schedule 13G reporting 7.7% ownership - Stock Titan
Number of shareholders of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Number of shareholders of OKYO Pharma Limited – GETTEX:OK11 - TradingView
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April - MarketBeat
OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting - Proactive financial news
OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver - TipRanks
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May - The Manila Times
OKYO Pharma (NASDAQ: OKYO) showcases urcosimod NCP data at Eyecelerator and ARVO - Stock Titan
Okyo Pharma Limited Azioni (OKYO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):